Company / Net Income
Cardiff Oncology, Inc. Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$45.9M
FY2025
5-year range
-$45.9M / -$19.3M
FY2021-FY2025
Trend
-10.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Net Income has declined for 4 consecutive years, from -$19M in FY2021 to -$46M in FY2025.
Based on SEC 10-K filings.
-$46M in FY2025.
Declined from -$39M to -$46M over the past 2 years.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Cardiff Oncology, Inc.'s net income has declined for 4 consecutive years.
- In FY2025, net income decreased 10.6% year-over-year.
- Peak net income was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -6.67 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$45.9M | -10.6% |
| FY2024 | -$41.4M | -7.1% |
| FY2023 | -$38.7M | -36.8% |
| FY2022 | -$28.3M | -46.5% |
| FY2021 | -$19.3M | +0.0% |
| FY2020 | -$19.3M | -17.6% |
| FY2019 | -$16.4M | +34.1% |
| FY2018 | -$24.9M | +36.5% |
| FY2017 | -$39.2M | -173.7% |
| FY2016 | -$14.3M | +47.9% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026